ConductScience.org, home

Gene · 2042

EPHA3: EPH receptor A3

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. EPHA3: EPH receptor A3. Genes, record 2042. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2042

On this page

Gene

Symbol
EPHA3
HGNC
Name
EPH receptor A3
HGNC
NCBI Gene ID
2042
NCBI Gene
HGNC ID
HGNC:3387
HGNC
Ensembl
ENSG00000044524
NCBI Gene
Aliases
EK4, ETK, ETK1, HEK, HEK4, TYRO4
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P29320Ephrin type-A receptor 398328Ensembl, GeneID, HGNC

Source UniProt

Patents93

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
US 12636345 B22026-05-2656P29320Espacenet
JP 2026004568 A2026-01-1445079P29320Espacenet
EP 4650780 A22025-11-196281P29320Espacenet
EP 4641201 A22025-10-296043P29320Espacenet
JP 2025147176 A2025-10-064806P29320Espacenet
WO 2025194019 A12025-09-182P29320Espacenet
JP 2025529142 A2025-09-041414P29320Espacenet
JP 2025529142 A2025-09-046272P29320Espacenet
US 12371689 B22025-07-291414P29320Espacenet
US 12371689 B22025-07-296272P29320Espacenet

1 to 10 of 93

See all 93 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
KB-004CHEMBL2109398Ephrin type-A receptor 3 inhibitorINHIBITORChEMBL
VANDETANIBCHEMBL24828Ephrin receptor inhibitorINHIBITORChEMBL

Trials99

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT06482086VANDETANIBPHASE2ClinicalTrials.gov
NCT04211337VANDETANIBPHASE32024-06-13ClinicalTrials.gov
NCT03630120VANDETANIBPHASE22021-01-22ClinicalTrials.gov
NCT03374943KB-004PHASE1ClinicalTrials.gov
NCT03291379VANDETANIBEARLY_PHASE12021-02-03ClinicalTrials.gov
NCT02638428VANDETANIBPHASE2ClinicalTrials.gov
NCT02530411VANDETANIBPHASE2ClinicalTrials.gov
NCT02495103VANDETANIBPHASE1/PHASE22021-01-26ClinicalTrials.gov
NCT02299999VANDETANIBPHASE2ClinicalTrials.gov
NCT02117167VANDETANIBPHASE2ClinicalTrials.gov

1 to 10 of 99

See all 99 trials

NIH grants1,326

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleEPHA3 papersNewest fiscal year
P30CA016672Cancer Center Support Grant242025
P30CA008748Cancer Center Support Grant122025
R35GM118062Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics112025
RM1HG009490Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease112025
P30CA012197Cancer Center Support Grant72025
P30CA030199Cancer Center Support Grant (CCSG)62025
P30CA068485Cancer Center Support Grant52025
T32CA009592Microenvironmental Influences in Cancer52025
ZIABC010441Biomolecular Recognition and Binding Mechanisms52025
P30CA015704Cancer Center Support Grant42025

1 to 10 of 1,326Source NIH's project files

See all 1,326 nih grants

Papers1,673

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression.Radiol Oncol202642704035PubTator, text miningPubMed
Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin.Med Oncol202642484926PubTator, text miningPubMed
Single-cell and spatial transcriptomics reveal lactate-active epithelial-immune cell crosstalk that reprograms the immune microenvironment in colorectal cancer.Transl Oncol202642320170PubTator, text miningPubMed
A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.Clin Cancer Res202642268288PubTator, text miningPubMed
The EphA3 Antibody Enhances CD47 Antibody-Mediated Phagocytosis by Repolarizing M2-Like Tumor-Associated Macrophages in a Preclinical Model of Recurrent Head and Neck Cancer.Onco Targets Ther202642164995PubTator, text miningPubMed
Functional significance of miR-218 in lung cancer.J Cancer Metastasis Treat202641924446PubTator, text miningPubMed
Reassessing Transketolase Assays: Methodological Considerations for Detecting Functional Thiamine Deficiency.Ann N Y Acad Sci202641870883PubTator, text miningPubMed
BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Mol Biomed202641807883PubTator, text miningPubMed
CBX3:IL1RN Reflects Distinct Cellular States That Defines the Clinical Outcome of Oral Squamous Cell Carcinoma.Cancer Med202641803005PubTator, text miningPubMed
Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.Int J Med Sci202641799774PubTator, text miningPubMed

1 to 10 of 1,673

See all 1,673 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/2042

GET https://conductscience.org/api/genes/v1/2042/patents?page=2